Melanoma

Uveal Melanoma

Adjuvant Therapies

Stages 2B, 2C, or 3

Stages 3 or 4 resectable

Non-Mutation Specific

New study coming soon

New study coming soon

Stages 3 or 4, unresectable

Mutation Specific

BRAF V600 Mutation

NRAS Mutation

C-Kit Mutation

IRB#11848
Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

IRB#15661
Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

IRB#11313
A Phase II Study of Ipilimumab and HF10 for Stage IIIB/C, or IV Unresected or Metastatic Malignant Melanoma

IRB#15298
Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

IRB#116162
A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

IRB#11313
A Phase II Study of Ipilimumab and HF10 for Stage IIIB/C, or IV Unresected or Metastatic Malignant Melanoma

Please refer to Phase I studies for more clinical trial opportunities